Next Article in Journal
Biological Membrane Structure by Solid-State NMR
Previous Article in Journal
Molecular Mechanisms of Self-Incompatibility in Brassica
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
CIMB
Volume 2
Issue 4
10.21775/cimb.002.113
cimb-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Current Issues in Molecular Biology is published by MDPI from Volume 43 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Caister Press.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Ribozyme Pharmacokinetic Screening for Predicting Pharmacodynamic Dosing Regimens

by
Tom J. Parry
1,
Karyn S. Bouhana
2,
Karin S. Blanchard
2,
Pamela A. Pavco
2 and
Jennifer A. Sandberg
2,*
1
Human Genome Sciences, Inc., 9410 Key West Ave., Rockville, MD 20850, USA
2
Ribozyme Pharmaceuticals, Inc., 2950 Wilderness Place, Boulder, CO 80301, USA
*
Author to whom correspondence should be addressed.
Curr. Issues Mol. Biol. 2000, 2(4), 113-118; https://doi.org/10.21775/cimb.002.113
Submission received: 6 June 2000 / Revised: 3 August 2000 / Accepted: 12 September 2000 / Published: 1 October 2000
Versions Notes

Abstract

A significant amount of research has been devoted to the chemical stabilization of synthetic ribozymes, in part, so that applications to systemic disease can be explored. A nuclease-stabilized synthetic hammerhead ribozyme, ANGIOZYME, has been developed which targets the mRNA encoding a vascular endothelial growth factor receptor, Flt-1. Because the stimulation of this receptor may contribute to tumor neovascularization and subsequent tumor growth and metastasis, we have explored the systemic use of ANGIOZYME to down regulate this receptor in a syngeneic model of metastatic cancer. We describe here the application of pharmacokinetic analysis to the selection of a dosing regimen for pharmacodynamic screening in this murine cancer model. These studies demonstrate that the appropriate application of pharmacokinetic analysis is necessary for the optimization of systemic pharmacodynamic studies using synthetic ribozymes.

Share and Cite

MDPI and ACS Style

Parry, T.J.; Bouhana, K.S.; Blanchard, K.S.; Pavco, P.A.; Sandberg, J.A. Ribozyme Pharmacokinetic Screening for Predicting Pharmacodynamic Dosing Regimens. Curr. Issues Mol. Biol. 2000, 2, 113-118. https://doi.org/10.21775/cimb.002.113

AMA Style

Parry TJ, Bouhana KS, Blanchard KS, Pavco PA, Sandberg JA. Ribozyme Pharmacokinetic Screening for Predicting Pharmacodynamic Dosing Regimens. Current Issues in Molecular Biology. 2000; 2(4):113-118. https://doi.org/10.21775/cimb.002.113

Chicago/Turabian Style

Parry, Tom J., Karyn S. Bouhana, Karin S. Blanchard, Pamela A. Pavco, and Jennifer A. Sandberg. 2000. "Ribozyme Pharmacokinetic Screening for Predicting Pharmacodynamic Dosing Regimens" Current Issues in Molecular Biology 2, no. 4: 113-118. https://doi.org/10.21775/cimb.002.113

APA Style

Parry, T. J., Bouhana, K. S., Blanchard, K. S., Pavco, P. A., & Sandberg, J. A. (2000). Ribozyme Pharmacokinetic Screening for Predicting Pharmacodynamic Dosing Regimens. Current Issues in Molecular Biology, 2(4), 113-118. https://doi.org/10.21775/cimb.002.113

Article Metrics

Back to TopTop